Suppr超能文献

CHAT基因的一个遗传变异对阿尔茨海默病患者血浆可溶性ChAT水平的影响。

Influence of a genetic variant of CHAT gene over the profile of plasma soluble ChAT in Alzheimer disease.

作者信息

Rocha-Dias Patricia Fernanda, Simao-Silva Daiane Priscila, Silva Saritha Suellen Lopes da, Piovezan Mauro Roberto, Souza Ricardo Krause M, Darreh-Shori Taher, Furtado-Alle Lupe, Souza Ricardo Lehtonen Rodrigues

机构信息

Universidade Federal do Paraná (UFPR), Centro Politécnico, Programa de Pós-Graduação em Genética, Departamento de Genética, Curitiba, PR, Brazil.

Instituto de Pesquisa do Câncer (IPEC), Guarapuava, PR, Brazil.

出版信息

Genet Mol Biol. 2020 Nov 20;43(4):e20190404. doi: 10.1590/1678-4685-GMB-2019-0404. eCollection 2020.

Abstract

The choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) are fundamental to neurophysiological functions of the central cholinergic system. We confirmed and quantified the presence of extracellular ChAT protein in human plasma and also characterized ChAT and VAChT polymorphisms, protein and activity levels in plasma of Alzheimer's disease patients (AD; N = 112) and in cognitively healthy controls (EC; N = 118). We found no significant differences in plasma levels of ChAT activity and protein between AD and EC groups. Although no differences were observed in plasma ChAT activity and protein concentration among ChEI-treated and untreated AD patients, ChAT activity and protein levels variance in plasma were higher among the rivastigmine-treated group (ChAT protein: p = 0.005; ChAT activity: p = 0.0002). Moreover, AD patients homozygous for SNP rs1880676 A allele exhibited higher levels of ChAT activity. Considering this is the first study to report the influence of genetic variability of CHAT locus over ChAT activity in AD patients plasma, it opens a new set of important questions on peripheral cholinergic signaling in AD.

摘要

胆碱乙酰转移酶(ChAT)和囊泡乙酰胆碱转运体(VAChT)对中枢胆碱能系统的神经生理功能至关重要。我们证实并定量了人血浆中细胞外ChAT蛋白的存在,还对阿尔茨海默病患者(AD;N = 112)和认知健康对照者(EC;N = 118)血浆中的ChAT和VAChT多态性、蛋白及活性水平进行了表征。我们发现AD组和EC组之间血浆ChAT活性和蛋白水平无显著差异。虽然在接受胆碱酯酶抑制剂(ChEI)治疗和未治疗的AD患者中,血浆ChAT活性和蛋白浓度未观察到差异,但在接受卡巴拉汀治疗的组中,血浆ChAT活性和蛋白水平的变异性更高(ChAT蛋白:p = 0.005;ChAT活性:p = 0.0002)。此外,SNP rs1880676 A等位基因纯合的AD患者表现出更高水平的ChAT活性。鉴于这是第一项报道CHAT基因座遗传变异性对AD患者血浆中ChAT活性影响的研究,它开启了关于AD外周胆碱能信号传导的一系列新的重要问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5700/7783728/b227942f97a1/1415-4757-GMB-43-4-e20190404-gf01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验